Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (I),

• wherein:
• R1 is aryl, heteroaryl, aralkyl, heteroaralkyl, lower alkyl, lower-alkoxy-benzyl, lower-alkoxy-carbonyl-lower-alkyl, halo-lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, (CH2)s-aryl, (CH2)s-heteroaryl or (CH2)s-cycloalkyl, where said aryl, heteroaryl, aralkyl, heteroaralkyl (CH2)s-aryl, (CH2)s-heteroaryl or (CH2)s-cycloalkyl is unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy, cyano, lower-alkoxy-carbonyl, halo-lower-alkyl, phenyl-(oxo-lower-alkyl) and hydroxy-lower-alkyl;
• p is 0 or 1;
• s is 0, 1 or 2;
• and
• R2 is phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, hydroxy, halo-lower-alkyl, lower alkoxy, trifluoromethoxy, aminocarbonyl, lower-alkyl, nitro, cyano, sulfonamido, lower-alkyl-sulfonyl, lower acyl and lower-alkoxy-carbonyl,
• halo-lower-alkyl,
• unsubstituted or substituted naphthyl,
• biphenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of acetyl, halogen, lower-alkoxy and lower-alkyl,
• a 5- or 6-membered monocyclic heterocycle with 1-3 atoms selected from N, O and S, which may be unsubstituted or substituted with halogen, lower-alkyl, unsubstituted or substituted phenyl, or halo-lower-alkyl, or
• unsubstituted or substituted benzothiophene,
• or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.

A method of treating a metabolic disorder, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to formula (I),

• wherein:
• R1 is aryl, heteroaryl, aralkyl, heteroaralkyl, lower alkyl, lower-alkoxy-benzyl, lower-alkoxy-carbonyl-lower-alkyl, halo-lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, (CH2)s-aryl, (CH2)s-heteroaryl or (CH2)s-cycloalkyl, where said aryl, heteroaryl, aralkyl, heteroaralkyl (CH2)s-aryl, (CH2)s-heteroaryl or (CH2)s-cycloalkyl is unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy, cyano, lower-alkoxy-carbonyl, halo-lower-alkyl, phenyl-(oxo-lower-alkyl) and hydroxy-lower-alkyl;
• p is 0 or 1;
• s is 0, 1 or 2;
• and
• R2 is phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, hydroxy, halo-lower-alkyl, lower alkoxy, trifluoromethoxy, aminocarbonyl, lower-alkyl, nitro, cyano, sulfonamido, lower-alkyl-sulfonyl, lower acyl and lower-alkoxy-carbonyl,
• halo-lower-alkyl,
• unsubstituted or substituted naphthyl,
• biphenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of acetyl, halogen, lower-alkoxy and lower-alkyl,
• a 5- or 6-membered monocyclic heterocycle with 1-3 atoms selected from N, O and S, which may be unsubstituted or substituted with halogen, lower-alkyl, unsubstituted or substituted phenyl, or halo-lower-alkyl, or
• unsubstituted or substituted benzothiophene,
• or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.